Accuracy of the New Injury Severity Score in Evaluating Patients With Blunt Trauma
ConditionTrauma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAl-Nahrain University
About this trial
The goal of this prospective observational study is to evaluate the predictive utility of the New Injury Severity Score (NISS) in determining mortality outcomes among blunt trauma patients admitted to the Emergency Department of Kadhimiya Educational Hospital, Iraq.
The main questions it aims to answer are:
How accurately does NISS predict mortality in blunt trauma patients? What is the performance of NISS in predicting secondary outcomes, such as the need for intensive care and length of hospital stay?
Participants will:
Be assessed using the NISS score upon their admission to the emergency department.
Have their clinical outcomes, including mortality, need for intensive care, and hospital stay, monitored throughout their hospitalization.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Trauma patients admitted to the emergency department, presenting with blunt trauma, such as from motor vehicle accidents, falls, or assaults.
Patients with adequate documentation of anatomical injuries and physiological parameters required for NISS calculation.
Injury assessment and NISS calculation completed within the first 6 hours of arrival to ensure accuracy and consistency in trauma evaluation.
Disqualifiers
Patients under 18 years, pregnant women, or those with pre-existing medical conditions that may alter trauma scoring accuracy or management outcomes.
Patients presenting with medical emergencies, terminal illnesses, or conditions unrelated to blunt trauma to ensure focus on trauma-specific evaluations.
Patients declared dead on arrival or who do not receive active treatment in the emergency department.
Patients or their families refusing participation or withdrawing consent at any stage of the study.
Trial population
The study population will consist of trauma patients presenting to the Emergency Department of Al-Kadhmia Teaching Hospital during the study period. These patients will represent a diverse demographic and clinical profile, including individuals with different injury mechanisms such as motor vehicle accidents, falls, assaults, and sports-related injuries, as well as varying injury severities and outcomes. The study will specifically focus on patients for whom the New Injury Severity Score (NISS) can be reliably applied. This includes patients with blunt trauma, where injury severity can be accurately assessed using clinical and radiological data.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
In hospital mortality
Mortality (death) during hospitalization.
Time frame
In-Hospital Phase (average of 6 days through discharge); Post-Discharge Follow-Up: Day 7, Day 302
Accuracy Assessment of the New Injury Severity Score (NISS)
Range:0 to 75, with higher scores indicating worse outcomes and greater injury severity.
Time frame
the first 6 hours after ER admissionSecondary outcomes
1
Length of Hospitalization
The total duration of a patient's stay in the hospital, measured from the date of admission to the date of discharge. This includes all days spent in general wards, intensive care units (ICU), and other hospital departments as part of their treatment course.
Time frame
Up to discharge, an average of 6 days2
Number of Participants Requiring ICU Admission
The requirement for admission to the intensive care unit (ICU) is determined by the presence of severe clinical deterioration, significant complications, or the need for advanced monitoring and life-support measures.
Time frame
Up to discharge, an average of 6 days3
The Number of Participants Who Require Surgical Intervention
need for surgical intervention during a trauma patient's hospital stay.
Time frame
Up to discharge, an average of 6 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov